Polyphor Ltd and Axxam SpA Announce Ion Channel Collaboration
News Apr 13, 2010
Polyphor Ltd and Axxam SpA have announced a joint discovery agreement with a synergistic combination of their discovery platforms.
Under the terms of the collaboration the two companies will work together to discover and develop innovative drug candidates for selected therapeutic areas such as pain, inflammation, and metabolic disorders.
Axxam will apply its expertise and outstanding Hit Discovery platforms and capabilities, and Polyphor will provide its unique, proprietary PEM finder® library for screening together with its expertise in medicinal chemistry, drug discovery and development. The collaboration comprises several discovery programs addressing attractive ion channel based targets.
Scientists have developed a way to identify the beginning of every gene — known as a translation start site or a start codon — in bacterial cell DNA with a single experiment and, through this method, they have shown that an individual gene is capable of coding for more than one protein.
By leveraging an organ-on-a-chip model and a bioreactor, four human gut metabolites have been identified that can help explain the enhanced sensitivity of the human colon towards enterohemorrhagic E. coli, which is responsible for more than 100,000 infections per year in the USA alone.READ MORE